Electrophysiologic and antiarrhythmic effects of oral encainide in patients with atrioventricular nodal reentry or nodoventricular reentry

William M. Miles, Mau Song Chang, James J. Heger, Robert L. Rinkenberger, Douglas P. Zipes, Eric N. Prystowsky

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Three patients with drug-resistant atrioventricular (AV) nodal reentrant tachycardia and two patients with reciprocating tachycardia associated with nodoventricular pathways received oral encainide after a control drug-free electrophysiologic study. In one patient with AV nodal reentry, encainide prolonged anterograde AV nodal conduction, produced complete ventriculoatrial (VA) block, and prevented tachycardia induction. Encainide had no effect on AV or VA conduction in the second patient with AV nodal reentry, and tachycardia with similar cycle length was still induced. The third patient was not studied while receiving encainide, but spontaneous AV nodal reentrant tachycardia occurring multiple times daily was abolished. In both patients with nodoventricular pathways, anterograde AV nodal and VA conduction were prolonged by encainide and tachycardia was no longer inducible. Two patients with AV nodal reentry were given long-term encainide therapy and have been free of recurrent arrhythmias for 16 and 30 months. One patient with a nodoventricular pathway has been without arrhythmia recurrence after 73 months of encainide therapy; the other patient required addltion of propranolol to encainide because of recurrent tachycardia. We conclude that encainide can prolong anterograde AV nodal and VA conduction and prevent induced and spontaneous tachycardia in some patients with drug-resistant and highly symptomatic AV nodal or nodoventricular reentry.

Original languageEnglish
Pages (from-to)26-33
Number of pages8
JournalAmerican Heart Journal
Volume114
Issue number1 PART 1
DOIs
StatePublished - 1987

Fingerprint

Encainide
Accessory Atrioventricular Bundle
Atrioventricular Nodal Reentry Tachycardia
Tachycardia
Cardiac Arrhythmias
Reciprocating Tachycardia
Drug and Narcotic Control
Propranolol
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Electrophysiologic and antiarrhythmic effects of oral encainide in patients with atrioventricular nodal reentry or nodoventricular reentry. / Miles, William M.; Chang, Mau Song; Heger, James J.; Rinkenberger, Robert L.; Zipes, Douglas P.; Prystowsky, Eric N.

In: American Heart Journal, Vol. 114, No. 1 PART 1, 1987, p. 26-33.

Research output: Contribution to journalArticle

Miles, William M. ; Chang, Mau Song ; Heger, James J. ; Rinkenberger, Robert L. ; Zipes, Douglas P. ; Prystowsky, Eric N. / Electrophysiologic and antiarrhythmic effects of oral encainide in patients with atrioventricular nodal reentry or nodoventricular reentry. In: American Heart Journal. 1987 ; Vol. 114, No. 1 PART 1. pp. 26-33.
@article{a8c80ef686ca443dabc4ab97dd69a5e1,
title = "Electrophysiologic and antiarrhythmic effects of oral encainide in patients with atrioventricular nodal reentry or nodoventricular reentry",
abstract = "Three patients with drug-resistant atrioventricular (AV) nodal reentrant tachycardia and two patients with reciprocating tachycardia associated with nodoventricular pathways received oral encainide after a control drug-free electrophysiologic study. In one patient with AV nodal reentry, encainide prolonged anterograde AV nodal conduction, produced complete ventriculoatrial (VA) block, and prevented tachycardia induction. Encainide had no effect on AV or VA conduction in the second patient with AV nodal reentry, and tachycardia with similar cycle length was still induced. The third patient was not studied while receiving encainide, but spontaneous AV nodal reentrant tachycardia occurring multiple times daily was abolished. In both patients with nodoventricular pathways, anterograde AV nodal and VA conduction were prolonged by encainide and tachycardia was no longer inducible. Two patients with AV nodal reentry were given long-term encainide therapy and have been free of recurrent arrhythmias for 16 and 30 months. One patient with a nodoventricular pathway has been without arrhythmia recurrence after 73 months of encainide therapy; the other patient required addltion of propranolol to encainide because of recurrent tachycardia. We conclude that encainide can prolong anterograde AV nodal and VA conduction and prevent induced and spontaneous tachycardia in some patients with drug-resistant and highly symptomatic AV nodal or nodoventricular reentry.",
author = "Miles, {William M.} and Chang, {Mau Song} and Heger, {James J.} and Rinkenberger, {Robert L.} and Zipes, {Douglas P.} and Prystowsky, {Eric N.}",
year = "1987",
doi = "10.1016/0002-8703(87)90302-4",
language = "English",
volume = "114",
pages = "26--33",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "1 PART 1",

}

TY - JOUR

T1 - Electrophysiologic and antiarrhythmic effects of oral encainide in patients with atrioventricular nodal reentry or nodoventricular reentry

AU - Miles, William M.

AU - Chang, Mau Song

AU - Heger, James J.

AU - Rinkenberger, Robert L.

AU - Zipes, Douglas P.

AU - Prystowsky, Eric N.

PY - 1987

Y1 - 1987

N2 - Three patients with drug-resistant atrioventricular (AV) nodal reentrant tachycardia and two patients with reciprocating tachycardia associated with nodoventricular pathways received oral encainide after a control drug-free electrophysiologic study. In one patient with AV nodal reentry, encainide prolonged anterograde AV nodal conduction, produced complete ventriculoatrial (VA) block, and prevented tachycardia induction. Encainide had no effect on AV or VA conduction in the second patient with AV nodal reentry, and tachycardia with similar cycle length was still induced. The third patient was not studied while receiving encainide, but spontaneous AV nodal reentrant tachycardia occurring multiple times daily was abolished. In both patients with nodoventricular pathways, anterograde AV nodal and VA conduction were prolonged by encainide and tachycardia was no longer inducible. Two patients with AV nodal reentry were given long-term encainide therapy and have been free of recurrent arrhythmias for 16 and 30 months. One patient with a nodoventricular pathway has been without arrhythmia recurrence after 73 months of encainide therapy; the other patient required addltion of propranolol to encainide because of recurrent tachycardia. We conclude that encainide can prolong anterograde AV nodal and VA conduction and prevent induced and spontaneous tachycardia in some patients with drug-resistant and highly symptomatic AV nodal or nodoventricular reentry.

AB - Three patients with drug-resistant atrioventricular (AV) nodal reentrant tachycardia and two patients with reciprocating tachycardia associated with nodoventricular pathways received oral encainide after a control drug-free electrophysiologic study. In one patient with AV nodal reentry, encainide prolonged anterograde AV nodal conduction, produced complete ventriculoatrial (VA) block, and prevented tachycardia induction. Encainide had no effect on AV or VA conduction in the second patient with AV nodal reentry, and tachycardia with similar cycle length was still induced. The third patient was not studied while receiving encainide, but spontaneous AV nodal reentrant tachycardia occurring multiple times daily was abolished. In both patients with nodoventricular pathways, anterograde AV nodal and VA conduction were prolonged by encainide and tachycardia was no longer inducible. Two patients with AV nodal reentry were given long-term encainide therapy and have been free of recurrent arrhythmias for 16 and 30 months. One patient with a nodoventricular pathway has been without arrhythmia recurrence after 73 months of encainide therapy; the other patient required addltion of propranolol to encainide because of recurrent tachycardia. We conclude that encainide can prolong anterograde AV nodal and VA conduction and prevent induced and spontaneous tachycardia in some patients with drug-resistant and highly symptomatic AV nodal or nodoventricular reentry.

UR - http://www.scopus.com/inward/record.url?scp=0023218539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023218539&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(87)90302-4

DO - 10.1016/0002-8703(87)90302-4

M3 - Article

C2 - 3111237

AN - SCOPUS:0023218539

VL - 114

SP - 26

EP - 33

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 1 PART 1

ER -